The incidence of oesophageal adenocarcinoma (AC) 
Tissue specimens

Twenty biopsies of normal squamous oesophagus (in patients without
 Barrett' 
RT-PCR and PCR
Total RNA or DNA prepared from cells or frozen tissue using Triozol Reagent (Invitrogen, Carlsbad, CA, USA) according to the protocol supplied by the manufacturer was subjected to RT-PCR or PCR, respectively, using primers chosen to amplify a gene fragment of about 300-600 bases. Primers were synthesized by Sigma (Genosys, Woodlands, TX, USA) and are listed in Table 2 . The conditions used were as follows: 95°C (2 min.), followed by 40 cycles of 95°C (30 sec.) , 58°C (30 sec.) and 72°C (30 sec.) . Table 2 , and conditions were as described for RT-PCR. Methylated sites within the PCR amplified regions were determined by sequencing the purified MSP products. Table 2 , and PCR conditions were as described for RT-PCR.
Methylation-specific PCR (MSP)
CpG
Q-PCR and Q-MSP
Bisulphite sequencing
Two micrograms genomic DNA was bisulphite-treated and used for PCR amplification of a 270 base pair region with universal primers listed in Table 2 , and conditions described for RT-PCR. The PCR product was gelpurified and sequenced using the same primers. 
Chromatin immunoprecipitation (ChIP)
Statistical analyses
Correlation of ARF expression with clinical outcome
Among the 76 AC patients whose tumours were analysed for ARF expression in Figure 1A , clinical data relating to disease stage and survival were available for 47 patients ( [26] , and monoallelic methylation of the p16INK4a promoter in HCT116 colon cancer cells has been reported [27] . (Fig. 2B, ARF) , and the presence of both methylated and unmethylated ARF bands following MSP analysis (Fig. 2B, M Figure 2A , using the same methylation-specific primers as were used in Figure 2A . The results, shown schematically in Figure 2C, (Fig.  2B) , the direct sequence analysis of MSP products (Fig. 2C) , and the gene dosage analysis and bisulphite sequence analysis of genomic DNA (Fig. 2D) Figure 3A (ARF) and Figure 3A (ARF+aza)). GAPDH expression served as a control (Fig. 3A [GAPDH+aza] ). This treatment also resulted in undetectable levels of CpG methylation of ARF in all 9 BE and carcinoma cell lines (Fig. 3A, M, U [28, 29] . Figure 3C , the ARF gene was found to be associated with chromatin containing histone H3-K9-Me3, H3-K9-Me2 and H3-K27Me only in the three carcinoma cell lines, SEG1, TE7 and OC1 (Fig. 3C) (Fig. 3C) . Input ARF levels were the same in all cases (Fig. 3C, ARF (Fig. 3D) , consistent with a previous report [29, 30] . Input ARF levels were the same in all cases (Fig. 3D, ARF [33] , is expressed from a unique promoter, and it located some 20 kilobases upstream of the first exon of the p16INK4A gene, so deletion or methylation of one of the genes can occur without affecting the other, and this has been documented [34] [35] [36] . Our preliminary studies on a small sample set of BE specimens suggests that ARF and p16INK4a abnormalities arise independently of each other in pre-malignant lesions, but a further full scale study is needed to confirm this. Loss of wild-type p53 expression occurs in some 50-70% patients with BE and AC, and correlates with increased aneuploidy [37] , increased risk of progression [37] , and with poor prognosis [38] . In our analysis of BE specimens, complete loss of ARF expression occurred in some 20% of BE specimens and 75% of AC specimens, indicating that its occurrence was frequent and likely to occur in many specimens simultaneously with mutation or deletion of p53. ARF plays a well-described role in the p53 pathway and in certain cancers [39, 40] , a reciprocal pattern of abnormalities has been observed for p53 and ARF, consistent with their action in a common pathway. However, the high frequency of both abnormalities in oesophageal cancer suggests that the two abnormalities contribute independently to disease progression in this disease, and is consistent with published evidence of a p53-independent activity for ARF in mammalian cells [41, 42] .
exon 2). To determine how CpG island methylation of the ARF gene correlates with silencing of ARF in AC and BE, we carried out a methylation-specific PCR analysis (MSP) on bisulphite-treated genomic DNA derived from these cell lines (the amplified region, which falls within the 5Ј-UTR (untranslated region) and exon 1ß, is indicated by arrows in Fig. 2C). We found that normal oesophageal epithelial cells (HET1A) displayed only the unmethylated band, while all of the BE and carcinoma cell lines displayed both methylated and unmethylated bands (Fig. 2A, M, U). We have also observed lack of methylation of ARF in an additional cell line, BJ-1, derived from immortalized normal fibroblasts (not shown), adding additional support to the likelihood that methylation of this region in cultured
We ruled out cellular heterogeneity as a source of the methylated and unmethylated bands by showing that single cell-derived clones of the TE7 cell line (ARF-) were identical to the parental TE7 cell line with respect to ARF expression
C and a U (T), as would be expected if only one of the two alleles were protected by methylation. Similar results were observed for the remainder of the sequence, and for Gihtert and SEG1 (not shown). Taken together, the results of the cell cloning analysis
Activation of ARF expression by 5-aza-2Ј-deoxycytidine
To demonstrate a functional role for the observed CpG methylation of ARF, we carried out an experiment with the DNA demethylating agent, 5-aza-2Ј-deoxycytidine (5-aza-CdR), followed by RT-PCR in the 3 BE cell lines and the 6 carcinoma cell lines (Fig. 3A). Treatment of cell lines with 1M 5-aza-CdR for 24 hrs, followed by culturing for an additional 48 hrs, resulted in activation of ARF expression in the 3 carcinoma cell lines that had lacked ARF expression (SEG1, TE7, OC1, compare
Correlation of histone H3 methylation with complete silencing of ARF
Histone H3 di and trimethylation on lysine 9 (K9), and di and trimethylation on lysine 27 (K27) have been implicated as important epigenetic mechanisms of gene silencing in cancer
We therefore carried out a Chromatin Immunoprecipitation (ChIP) analysis using an antibody specific for histone H3 trimethylated lysine 9 (H3-K9-Me3), or using an antibody with dual specificity for the dimethylated form of histone H3 lysine K9 (H3-K9-Me2) and the di and trimethylated forms of lysine 27 (H3-K27-Me), followed by PCR analysis of the associated ARF sequences, to investigate the presence of this modification on ARF alleles in the series of cell lines examined above. As shown in
input). Controls (no antibody) were negative in all cases (not shown). The results suggest that histone methylationinduced silencing of ARF could also predispose to malignant transformation and to disease progression in AC.
Association of methylated histone H3 with unmethylated ARF DNA
Fig. 2 ARF expression and gene methylation status in NE, BE and carcinoma cell lines. (A) RT-PCR analysis of ARF expression (ARF) and GAPDH expression (GAPDH) in the normal
CpG methylation is a common mechanism of tumour suppressor gene silencing in cancer [15] , and CpG methylation of the first exon and proximal promoter of ARF is well documented in other cancers and cancer-derived cell lines [43, 44] . Methylation of lysines 9 and 27 of the N-terminal domain of histone H3, is also a mark of silenced genes and aberrant methylation of these residues has been implicated in gene silencing in cancer [28, 29] . CpG methylation can be associated with histone H3 methylation of K9 and K27, and epigenetic changes at the level of DNA and histone can cooperate in gene silencing [45] . However, long-range epigenetic silencing of gene expression due solely to histone methylation without DNA methylation has also been described [46] . Our results suggest that either DNA or histone H3 methylation can provide the primary mechanism of ARF gene silencing in oesophageal cancer, and that each appears to be sufficient to maintain stable silencing. The TE7 cell line we have used has recently been reported to be of squamous cell carcinoma origin [47] , but was still considered to be a useful addition to our panel of lines to determine the mechanism of silencing, however.
Consistent with an earlier study [29] , we find that both DNA and histone methylations are reversible with 5-aza-CdR, and that this treatment reactivates ARF expression. These results provide additional rationale for the clinical application of demethylating agents such as 5-aza-cytidine or 5-aza-2Ј-deoxycytidine [48] , or for specific histone demethylating approaches [28] to prevent tumourigenic transformation of pre-malignant lesions and possibly to reverse oesophageal malignancy. 
Fig. 3 Epigenetic changes affecting the ARF gene and associated histones in BE and carcinoma cell lines, and responses to 5-aza-CdR treatment. (A) RT-PCR analysis of ARF expression (ARF+aza) and GAPDH expression (GAPDH+aza) in the indicated BE and carcinoma cell lines after treatment with 5-aza-CdR. MSP analysis using methylated-specific (M+aza) and unmethylated-specific (U+aza) primers for the 5Ј-UTR/exon 1␤ region of the ARF gene in the same series of cell lines after treatment with 5-aza-CdR. (B) Quantitation by Q-PCR of 5-aza-CdR-induced changes in ARF expression (relative to GAPDH internal control) in the 3 BE cell lines and the 3 carcinoma cell lines that originally expressed ARF (bars represent averages of triplicate assays, with standard deviations shown). (C) ChIP analysis of ARF 5Ј-UTR
